CGON Insider Trading

Insider Ownership Percentage: N/A
Insider Buying (Last 12 Months): $12,662,968.00
Insider Selling (Last 12 Months): $0.00

CG Oncology Insider Trading History Chart

This chart shows the insider buying and selling history at CG Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

CG Oncology Share Price & Price History

Current Price: $29.50
Price Change: Price Increase of +0.53 (1.83%)
As of 05/22/2024 01:26 PM ET

This chart shows the closing price history over time for CGON up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365

CG Oncology Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/29/2024Corleen M RocheCFOBuy2,000$19.00$38,000.002,000View SEC Filing Icon  
1/29/2024Decheng Capital Global Life ScMajor ShareholderBuy400,000$19.00$7,600,000.00400,000View SEC Filing Icon  
1/29/2024Hong Fang SongDirectorBuy263,157$19.00$4,999,983.00613,928View SEC Filing Icon  
1/29/2024Vijay KasturiInsiderBuy1,315$19.00$24,985.001,315View SEC Filing Icon  
See Full Table

SEC Filings (Institutional Ownership Changes) for CG Oncology (NASDAQ:CGON)

26.56% of CG Oncology stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CGON by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

CG Oncology Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
5/17/2024RA Capital Management L.P.1,397,433$61.35M0.8%N/A2.097%Search for SEC Filing on Google Icon
5/16/2024California State Teachers Retirement System2,341$0.10M0.0%N/A0.004%Search for SEC Filing on Google Icon
5/16/2024Janus Henderson Group PLC1,521,432$66.76M0.0%N/A2.283%Search for SEC Filing on Google Icon
5/16/2024BVF Inc. IL1,884,191$82.72M2.3%N/A2.827%Search for SEC Filing on Google Icon
5/16/2024Blackstone Inc.25,000$1.10M0.0%N/A0.038%Search for SEC Filing on Google Icon
5/15/2024Price T Rowe Associates Inc. MD992,118$43.56M0.0%N/A1.489%Search for SEC Filing on Google Icon
5/15/2024Avoro Capital Advisors LLC700,000$30.73M0.4%N/A1.050%Search for SEC Filing on Google Icon
5/14/2024StemPoint Capital LP40,723$1.79M0.5%N/A0.061%Search for SEC Filing on Google Icon
5/14/2024Decheng Capital LLC5,458,810$239.64M32.1%N/A8.191%Search for SEC Filing on Google Icon
5/14/2024American International Group Inc.306,226$13.44M0.0%N/A0.460%Search for SEC Filing on Google Icon
5/13/2024Ameritas Investment Partners Inc.2,320$0.10M0.0%N/A0.003%Search for SEC Filing on Google Icon
5/10/2024Vanguard Group Inc.2,225,018$97.68M0.0%N/A3.339%Search for SEC Filing on Google Icon
5/7/2024TimesSquare Capital Management LLC224,073$9.84M0.1%N/A0.336%Search for SEC Filing on Google Icon
5/1/2024Capstone Investment Advisors LLC18,354$0.81M0.0%N/A0.028%Search for SEC Filing on Google Icon
5/1/2024BNP Paribas Financial Markets11,198$0.49M0.0%N/A0.017%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
CG Oncology logo
CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.
Read More on CG Oncology

Today's Range

Now: $29.50
Low: $28.58
High: $30.30

50 Day Range

MA: $36.87
Low: $25.84
High: $43.90

52 Week Range

Now: $29.50
Low: $25.77
High: $50.23

Volume

258,703 shs

Average Volume

667,390 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of CG Oncology?

CG Oncology's top insider investors include:
  1. Hong Fang Song (Director)
  2. Decheng Capital Global Life Sc (Major Shareholder)
  3. Corleen M Roche (CFO)
  4. Vijay Kasturi (Insider)
Learn More about top insider investors at CG Oncology.

Who are the major institutional investors of CG Oncology?

CG Oncology's top institutional shareholders include:
  1. Decheng Capital LLC — 8.19%
  2. Vanguard Group Inc. — 3.34%
  3. BVF Inc. IL — 2.83%
  4. Janus Henderson Group PLC — 2.28%
  5. RA Capital Management L.P. — 2.10%
  6. Price T Rowe Associates Inc. MD — 1.49%
Learn More about top institutional investors of CG Oncology stock.

Which institutional investors are buying CG Oncology stock?

Within the last quarter, CGON stock was bought by institutional investors including:
  1. Decheng Capital LLC
  2. Vanguard Group Inc.
  3. BVF Inc. IL
  4. Janus Henderson Group PLC
  5. RA Capital Management L.P.
  6. Price T Rowe Associates Inc. MD
  7. Avoro Capital Advisors LLC
  8. American International Group Inc.
In the last year, these company insiders have bought CG Oncology stock:
  1. Hong Fang Song (Director)
  2. Decheng Capital Global Life Sc (Major Shareholder)
  3. Corleen M Roche (CFO)
  4. Vijay Kasturi (Insider)
Learn More investors buying CG Oncology stock.